These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28799125)

  • 1. Non-polymer drug-eluting coronary stents.
    Kommineni N; Saka R; Khan W; Domb AJ
    Drug Deliv Transl Res; 2018 Aug; 8(4):903-917. PubMed ID: 28799125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer-Free Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents.
    Chen W; Habraken TC; Hennink WE; Kok RJ
    Bioconjug Chem; 2015 Jul; 26(7):1277-88. PubMed ID: 26041505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-eluting stents: current clinical experience.
    Grube E; Buellesfeld L
    Am J Cardiovasc Drugs; 2004; 4(6):355-60. PubMed ID: 15554720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus coating on heparinized stents prevents restenosis and thrombosis.
    Bae IH; Lim KS; Park DS; Shim JW; Lee SY; Jang EJ; Park JK; Kim JH; Jeong MH
    J Biomater Appl; 2017 May; 31(10):1337-1345. PubMed ID: 28436251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R;
    JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling drug release from polymer-free coronary stents with microporous surfaces.
    Vo TTN; Morgan S; McCormick C; McGinty S; McKee S; Meere M
    Int J Pharm; 2018 Jun; 544(2):392-401. PubMed ID: 29229513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxcel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study.
    Fischer D; Scheller B; Schäfer A; Klein G; Böhm M; Clever Y; Cremers B
    EuroIntervention; 2012 Aug; 8(4):450-5. PubMed ID: 22917728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
    Stone GW; Ellis SG; Cannon L; Mann JT; Greenberg JD; Spriggs D; O'Shaughnessy CD; DeMaio S; Hall P; Popma JJ; Koglin J; Russell ME;
    JAMA; 2005 Sep; 294(10):1215-23. PubMed ID: 16160130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design.
    Wessely R; Kastrati A; Mehilli J; Dibra A; Pache J; Schömig A
    Eur Heart J; 2007 Nov; 28(22):2720-5. PubMed ID: 17921531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo performance of a dual drug-eluting stent (DDES).
    Huang Y; Venkatraman SS; Boey FY; Lahti EM; Umashankar PR; Mohanty M; Arumugam S; Khanolkar L; Vaishnav S
    Biomaterials; 2010 May; 31(15):4382-91. PubMed ID: 20189244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Stettler C; Sangiorgi D; D'Ascenzo F; Kimura T; Briguori C; Sabatè M; Kim HS; De Waha A; Kedhi E; Smits PC; Kaiser C; Sardella G; Marullo A; Kirtane AJ; Leon MB; Stone GW
    Lancet; 2012 Apr; 379(9824):1393-402. PubMed ID: 22445239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents: from randomized trials to the real world.
    Saia F; Degertekin M; Lemos PA; Serruys PW
    Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.